This report presents the top-level overview of the drug phenomenon in Bulgaria, covering drug supply, use and public health problems as well as drug policy and responses. The statistical data reported relate to 2015 (or most recent year) and are provided to the EMCDDA by the national focal point, unless stated otherwise.
This report presents the top-level overview of the drug phenomenon in Turkey, covering drug supply, use and public health problems as well as drug policy and responses. The statistical data reported relate to 2015 (or most recent year) and are provided to the EMCDDA by the national focal point, unless stated otherwise.
This report presents the top-level overview of the drug phenomenon in Austria, covering drug supply, use and public health problems as well as drug policy and responses. The statistical data reported relate to 2015 (or most recent year) and are provided to the EMCDDA by the national focal point, unless stated otherwise.
The European market for hashish is currently one of the world’s largest and most profitable. About 647 tonnes of cannabis herb and 641 tonnes of hashish were consumed in the European Union in 2013 and the retail market has an overall value estimated conservatively to be about EUR 9.3 billion in 2013. This analysis describes how the supply of cannabis resin in Europe is changing in response to competition and other market developments.
Note that the online version contains additional interactive or audiovisual material not available in the PDF version.
Synthetic cannabinoids represent the largest group of substances currently monitored in Europe by the EMCCDA through the EU Early Warning System. Current knowledge on these substances and trends in production, availability, use and harms are presented in this analysis.
It is estimated that over 70 000 lives were lost to drug overdoses in Europe in the first decade of the twenty-first century. Reducing drug-related deaths therefore remains a major challenge for public health policy. This analysis describes some of the factors that increase the risk of fatal and non-fatal overdoses and a number of interventions developed to prevent these events.
Rising overdose deaths, the availability of new psychoactive substances and the growing health threat of potent synthetic opioids are among the issues highlighted in this year's European Drug Report.
This report presents the top-level overview of the drug phenomenon in Latvia, covering drug supply, use and public health problems as well as drug policy and responses. The statistical data reported relate to 2015 (or most recent year) and are provided to the EMCDDA by the national focal point, unless stated otherwise.
This is the final version of the questionnaire on drug use among prisoners at European level. The questionnaire is the results of several years of work in the field of drugs and prison, which has included the agreement on a methodological framework or monitoring drug and prison in Europe, the analysis of existing questionnaires and a discussion among high level experts from several European countries and international organizations.
Drug use can reduce the ability to drive a motor vehicle safely on the public road. European countries have developed various legal mechanisms to address this issue, using laws on road traffic or on drug control. This topic overview briefly describes the national laws in EU Member States and Norway, along with EU legislation, on drugs and driving.
The EMCDDA and the University Institute of Lisbon (ISCTE-IUL) will be strengthening their cooperation.
Leading European and international experts are meeting in Lisbon this week for meetings around the theme of the internet, the exploitation of cyberspace and the transformational nature of new technologies.
The EMCDDA has published today its new Strategy 2025, which sets out an ambitious course of travel for the agency over the next decade.
This strategy sets out an ambitious course of travel for the agency to 2025. It presents a vision to contribute to a healthier and more secure Europe, through better informed drug policy and action. Adopted unanimously by the agency’s key stakeholders in 2016, the strategy is the result of a year-long, in-depth analysis of the environment in which the EMCDDA operates. This analysis focused, in particular, on customer needs and a critical review of our internal capacity to meet them.
This document gives an overview of the drug-related deaths (DRD) indicator, one of five key epidemiological indicators used by the EMCDDA for the collection and interpretaion of harmonised, good quality data at European level. It is written in an easy to understand manner and is intended for a wide readership.
What do the latest data tell us about the European drug market? What are the new trends in drug use among European adults and school students?
This report provides an overview of the various types of brief interventions (BIs) currently used in European countries in the field of substance use, particularly illicit drugs. Targeted at policymakers and practitioners alike, it covers more than 30 BIs carried out in the EU and serves as a starting point for preparing concrete proposals to improve the evidence base on this topic.
The European Facility Survey Questionnaire (EFSQ) is a data collection instrument applicable in any European country or in any country worldwide interested in surveying facilities that provide interventions to drug users. The aim of the EFSQ is to collect information from the facilities across drug treatment systems on their administrative characteristics, client utilisation, staffing and quality management, and core interventions, while accounting for their diversity.
At a time of increased debate on the laws controlling the use of cannabis in the European Union, this report answers some of the questions most often asked about cannabis legislation. Using a question and answer format, basic definitions and the obligations of countries under international law are set out in a section on ‘What is cannabis and what are countries’ obligations to control it?‘ Two following sections examine the links and disparities between the content of the laws and their guidelines on the one hand and the actual implementation of the laws on the other.
This publication presents the data and findings of the risk assessment on methyl 2-[[1-(cyclohexylmethyl)-1H-indole-3-carbonyl]amino]-3,3-dimethylbutanoate (MDMB-CHMICA), carried out by the extended Scientific Committee of the EMCDDA on 22 July 2016. MDMB-CHMICA is the first synthetic cannabinoid receptor agonist to be risk-assessed by the EMCDDA. On the basis of the Risk Assessment Report — and on the initiative of the European Commission — on 27 February 2017, the Council decided that MDMB-CHMICA should be subject to control measures across the Member States.
The central UN policy-making body in drug-related matters, opens its 60th session in Vienna.
The network will be collecting data from new hospital ‘sentinel’ centres in eight European cities
Community coalitions are a strategy to coordinate activities and resources to prevent adolescent substance use and delinquent behaviour. They can help mobilise communities in prevention and health promotion initiatives.
The Communities That Care (CTC) approach sets out to reduce adolescent health and behaviour problems. It does so by identifying strong risk factors and weak protective factors experienced by this group and then selecting tested and effective prevention and early intervention programmes to address them.
The documents published cover the period 2017-19.
The Justice and Home Affairs (JHA) agencies’ network was established in 2006 to boost cooperation in the migration and security fields and to develop synergies in areas of common interest, such as operational work, training and external relations. Since the EMCDDA and EIGE joined in 2011, the network has been composed of nine agencies (CEPOL, EASO, EIGE, EMCDDA, eu-LISA, Eurojust, Europol, FRA and Frontex).
The EMCDDA Single Programming Document (SPD) for the period 2017–19, which includes the 2017 work programme, is the first work programme to be implemented under the new EMCDDA Strategy 2025. Priority in 2017 will be given to improving core monitoring tasks and to operating the EU Early Warning System under a new regulation on new psychoactive substances, which is expected to enter into force in the course of the year.
MDMB-CHMICA is a synthetic cannabinoid and will be subject to ‘control measures’ throughout the EU.
In September 2016, the EMCDDA and Europol examined the available information on a new psychoactive substance N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide, commonly known as acryloylfentanyl, through a joint assessment. The two organisations concluded that sufficient information had been accumulated to merit the production of a Joint Report on acryloylfentanyl as stipulated by Article 5.1 of the Council Decision.
In this issue: Lisbon Addictions 2017 | Revamped Healthy Nightlife Toolbox |
EMCDDA chairs JHA agencies’ network | Germany enacts new law to control
new psychoactive substances | European drugs summer school 2017 |
EMCDDA products and services | Scientific Committee begins new mandate
The Directors of FRA and the EMCDDA are at the European Parliament today, presenting highlights and priorities for the network.